CA1304705C - Organic systems - Google Patents
Organic systemsInfo
- Publication number
- CA1304705C CA1304705C CA000554916A CA554916A CA1304705C CA 1304705 C CA1304705 C CA 1304705C CA 000554916 A CA000554916 A CA 000554916A CA 554916 A CA554916 A CA 554916A CA 1304705 C CA1304705 C CA 1304705C
- Authority
- CA
- Canada
- Prior art keywords
- hypertonic
- cells
- bacillus thuringiensis
- medium
- per
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
Abstract
IMPROVEMENTS IN OR RELATING TO ORGANIC SYSTEMS
Abstract of the Disclosure Process of transforming Bacillus thuringiensis cells involving the preparation of competent cells by growing them in a hypertonic aqueous meidum, treating such competent cells, optionally after treatment with lysozyme in a hypertonic medium, with exogenous DNA in the presence of polyethylene glycol, while maintaining the hypertonic status, and isolating and resuspending the thus treated Bacillus thuringiensis cells in hypertonic medium to allow expression.
Abstract of the Disclosure Process of transforming Bacillus thuringiensis cells involving the preparation of competent cells by growing them in a hypertonic aqueous meidum, treating such competent cells, optionally after treatment with lysozyme in a hypertonic medium, with exogenous DNA in the presence of polyethylene glycol, while maintaining the hypertonic status, and isolating and resuspending the thus treated Bacillus thuringiensis cells in hypertonic medium to allow expression.
Description
13~ S
Case 130-4004 I~PROVEHENTS IN OR RELATING TO ORGANIC SYST~S
The present invention relates to a method of transforming Bacillus thuringiensis cells.
The terms "transforming" and "transformation", as used herein are intended to relate to a mechanism of genetic transfer whereby exogenous DNA is introduced in a recipient bacterium, thereby inducing genetic changes in said recipient bacterium.
Bacillus thuringiensis (BT) are gram-positive bacteria containing a crystal protein, the delta-endotoxin (DET) which is toxic to the larvae of a number of insects. Depending on the sub-species, BT is used as a selective biological pesticide against different pests. The sub-species thuringiensis, alesti and dendrolimus are for example pathogenic against Lepidoptera: the sub-species israelensis, darmstadiensis 73-E-10-2, kyushuensis and morrisoni PG14 against Diptera; the sub-species tenebrionis against Coleoptera; the sub-species kurstaki HD-l, kenyae, aizawai and colmeri against Lepidoptera and Diptera, whereas the sub-species dakota, indiana, tokokuensis and kumamotoensis are not known to be toxic to any pests.
From the industrial and ecological point of vlew lt ls deslrable to have additlonal biological pesticides with different e.g. higher or broader spectrwn of activity.
This aim can, for example, be achieved by the development of new isolates from nature, by conjugatlon of bacteria or by transformation of bacteria.
Thus new BT strains with interestlng actlvity have been isolated recently (e.g. var. tenebrionis with activity against beetles) and recent successes with regard to the conjugation of BT strains have been reported as well.
Transformation of bacteria has the advantage that, if successful, it allows the introduction of specific genetic information into bacteria.
-` 13~7~. 5 Thus a gene coding for a DET has been cloned in various micro-organisms such as Escherichia coli, Bacillus subtilis and Pseudomonas fluorescens and even in higher plants (tobacco) by recombinant DNA
techniques, more specifically by transformation.
Such genetically manipulated organisms produce however low amounts of DET compared to the amounts produced by natural BT strains.
The commercial value of such organisms is accordingly questionable, at least as long as no way has been found to improve the expression of the exogenous DNA encoding for DET.
It would accordingly appear indicated to try and obtain a better expression of exogenous genes (DNA) by using a BT bacterium as recipient bacterium in transformation techniques.
Known transformation techniques are essentially effected employing either cells or protoplasts.
The transformation of cells implies the presence of competent cells, i.e. cells in a precise physiological stage allowing binding and uptake of exogenous DNA. There is however no evidence for the existence of competent BT cells.
The transformation of BT protoplasts by DNA has been reported to succeed only in very low yields, i.e. substantially lower than those obtained with the transformation of B. subtilis. The low yields may be partly due to the poor regeneration of the protoplasts, including the transformed protoplast. Although Shall et al. (Fundamental and applied aspects of invertebrate Pathology, edited by R.A. Samson, J.M. Vlak and D. Peters, 1986, page 402) report that they optimized the protoplasting procedure and developed improved regeneration media to transform BT or B. cereus with plasmid DNA, they do not specify the nature of the optimization or improvement.
The transformation frequencies indicated by Shall et al. are accordingly difficult to interprete.
The present invention now provides an improved method of transforming BT. It is based on the finding that BT microorganisms develop a so-called competence status when they are introduced in a hypertonic aqueous medium.
'' ~3~7nS
_ 3 - 130-4004 The term hypertonic as used herein refers to a medium which is hypertonic vis a vis the conventional BT (cell culture or growth) media.
The method of the invention involves the steps of a) growing BT cells in a hypertonic aqueous medium b) introducing in the cell culture obtained by step a) and in the presence of polyethylene glycol, exogenous DNA while maintaining the hypertonic status, and c) isolating and resuspending the thus treated BT cells in hypertonic aqueous medium to allow expression.
In principle any compound which does not pass the semi-permeable cell membrane and is not metabolized by or toxic to BT cell may be employed to obtain the desired hypertonic status. In general, the desired hypertonic status will conveniently be achieved with the aid of saccharides, particularly mono- or disaccharides, which are not metabolized by BT. Suitable examples of such saccharides are sucrose and lactose.
The concentration of saccharides to be employed to achieved the desired hypertonic status is conveniently of the order of 0.4 M
saccharide per litre of aqueous medium or higher. In general, good results will be obtained with concentrations which are essentially isotonic with respect to the BT cytoplasm. Such osmotic status is in general obtained with a concentration of from 0.4 M to 0.5 M of saccharides per litre of aqueous medium. Hlgher saccharides concentrations may however be employed, but offer in general no advantages.
The term "hypertonic" employed hereinafter refers to a status or medium as specifled hereinbefore.
It is important that the hypertoni~ conditions are essentially maintained throughout the various steps a) to c) of the process.
The hypertonic aqueous media should be essentially neutral, i.e.
they should conveniently have a pH of 7 + 2, more preferably of 7 + 1.
In addition to the saccharides (to maintain the hypertonic 13~9~7~S
status) and eventually buffers (to maintain an essentially neutral status of the medium) other ingredients may and will be added e.g. to allow growth and development of the BT culture when required, etc.
Such additional ingredients are conventional and known by those skilled in the art, they comprise e.g. nutrients and salts.
Examples of suitable nutrients are e.g. beef extract, yeast extract, peptones, tryptones, amino acids (e.g. tryptophan), nucleosides such as thymidine and the like.
Examples of suitable salts are NaCl and MgC12.6H20. A suitable hypertonic medium may contain from 0.05 to 0.1 M of salts per litre.
The salts wil comprise preferably magnesium salts, such as MgC12.6H20.
The BT cell culture (starting material) will conveniently be prepared and grown under conventional conditions, i.e. with aeration and at ambient temperature, in an appropriate nutrient medium, e.g. in the minimal medium disclosed by J. Spizizen in Proc. natl. Acad. Sci.
(Wash) 44, 171-175 (1958), eventually supplemented with amino acids, salts, e.g. catalytic amounts of a manganese salt such as MnS04, etc.
It is advantageous to employ in step a) a BT cell culture which is in the exponential growth phase.
The freshly prepared BT cell culture is then diluted in a hypertonic medium to a starting cell concentration of substantially less then 109 cells per ml, e.g. of 104 to 106 cells per ml and the cell culture is grown, in said hypertonic medium up until a cell concentration of slightly less than 109 cells per ml, e.g. 108 to 5.108 cells per ml medium i9 obtained-The hypertonic medium employed to dilute the freshly prepared BTcell culture is conveniently at 20 to 40C, e.g. at 37C. The culture is then allowed to grow at this temperature. Thorough aeration should of course be ascertained. A slight amount of silicon is conveniently added to the cell culture medium to prevent foaming.
When the desired final cell concentration (o slightly less than 109 cells per ml) is reached, the thus prepared competent BT cells may be treated with DNA in the presence of polyethylene glycol (PEG), according to step b) of the process of the invention.
~3~g7~S
It is however advantageous to treat the competent BT cells, obtained according to step a) of the invention, with moderate concentrations of lysozyme in hypertonic medium, and to isolate and resuspend the lysozyme treated BT cells in hypertonic medium, before subjecting them to process b). The amount of lysozyme to be employed should be less than that normally used for the preparation of protoplasts. Such amount (concentration) will of course depend on various factors such as the osmotic pressure of the medium, its temperature, the desired reaction time etc. In general a suitable lysozyme concentration is of 20 to 300 microgram, e.g. of 200 microgram per ml of hypertonic aqueous medium (which is substantially lower than the 2 to 15 mg per ml which would be normally required for protoplasting purposes). Adequate distribution of lysozyme in the cell culture medium should be ascertained. The reaction time will i.a.
depend on the concentration and the quality of the lysozyme solution employed. The optimum reaction time may be determined by standard assays.
The reaction temperature is conveniently between 20 to 40C, preferably above room temperature, e.g. at about 37~C.
During the lysozyme treatment the hypertonic status, as specified above, should be maintained.
The treatment with lysozyme is then terminated by centrifugation of the cell suspension and resuspension of the pellet in hypertonic medium, conveniently at room temperature.
The thus prepared 3T cell culture - obtalned according to step a), optionally followed by treatment with lysozyme - is then treated with DNA, e.g. plasmid DNA, in the presence of polyethylene glycol (PEG). For that purpose, the DNA as well as the PEG are employed as suspensions/solutions in a hypertonic solutions, such that the osmotic pressure of the cell suspension remains essentially unchanged after addition of DNA and PEG to said cell suspension.
The amount of PEG employed will be conveniently selected such that its concentration in the BT cell culture lies within the range of from lOOg to 400g per litre, e.g. at 300~ per litre cell culture medium.
13047~S
The transformation step b) can essentially be effected under the conditions known to be appropriate for conventional protoplast transformation processes.
Accordingly, the selection of the appropriate amount and type of PEG and of the appropriate amount of DNA to be employed can conveniently be made by those skilled in the art of protoplast transformation.
Thus, an example of PEG suitable for use in this process is PEG
6000.
DNA amounts of from lO0 nanogram to 20 microgram per 108 to 109 BT cells will in general allow good results.
The incubation is convenien~ly effected with gentle mixing at room temperature. Tlle required incubation time is short, in general of the order of a few minutes (see the example).
The suspension comprising the transformed cells is then worked up employing conventional methods but while securing the hypertonic status of the solvent of the cells (when in solution/suspension). Thus the suspension is for example diluted with hypertonic solution, the suspension mixed, centrifuged and the pellet resuspended in hypertonic medium.
The resulting suspension is then incubated at a temperature of 20 to 40C, e.g. at 37C, to allow expression. The suspension is conveniently aerated, employing e.g. a shakin~ water bath. An appropriate incubation time ls 30 nlit1utes to .~ hours, more preferably between 2 to 4 hours, e.g. 3 hours.
Appropriate dilutions of the thus obtained cèll cultures may then be placed on culture plates for determination of colony forming units (CFU). The transformation frequency may be determined by known methods employing standard techniques such as antibiotic containing culture plates, visual observation etc.
The method of the present invention allows the transformation of BT cells in high yields. Transformation allows gene cloning of genomic libraries in BT cells, cloning and expression of DET genes in BT, cloning and expression of in vitro and in vivo modified DET genes in 13C~4~S
BT, the synthesis of useful polypeptides, etc.
Where the transformed BT cells are intended for use as biological pesticides they are conveniently employed in insecticidal composition form, e.g. in suspension concentrate form or powder form. Such compositions may be obtained in conventional manner.
In the following non-limitative example the starting materials (BT cells and plasmid DNA) were selected such that the results are unambigous and cannot be due to plasmid interaction; the BT cells used as starting material did not contain plasmids, the plasmid DNA used as transforming agent encodes for resistance against tetra-cycline.
It will be appreciated that other BT cells and/or exogenous DNA, particularly plasmid DNA may be used in the method of the invention with similar results.
Temperatures are in centigrade and parts by weight unless specified otherwise.
- 13$~7(~5 EXAHPLE
Star_ing Materials Strain : Bacillus thuringiensis subsp. kurstaki HDl cry B, (obtained from M.-M. Lecadet, Institut Pasteur, Paris) having no plasmids.
DNA : pBC16.1 (Kraft. J. et al. (1978) Molec. gen. Genet. 162 :
59-67) extracted from HDl cry B (pBC16.1), in which it was introduced by conjugation via cell mating with B. subtilis BD224 (pBC16.1), coding for tetracycline resistance.
Media SA Trp : Spizizen minimal medium (Spizizen J. (1958) Proc. natl. Acad.
Scl (Wash.) 44 : 171-175) supplemented with 1% Casamino acids (Difco), 5xlO 6 M MnS04 and 20 ~g/ml Tryptophan.
Hypetonic medium (HM) :
Beef Extract1.50 g/l Peptone 5.00 g/l NaCl 3.50 g/l Sucrose171.15 g/l Maleic Acid2.32 g/l gC12 . 6H204.07 g/l pH 6.7 Luria Medium ~A? :
Tryptone 10 g/l Yeast Extract 5 g/l NaCl 10 g/l Agar (Difco Bacto) 15 g/l Thymidine20 mg/l Antibiotics : Tetracycline, 10-100 ~g/ml in LA plates 13~7(~5 Solutions SMM : Sucrose 171.15 g/l Maleic Acid 2.32 g/l gC12 . 6H204.07 g/l pH 6.5 PEG . PEG 6'000 40 g SMM ad 100 ml Lysozyme : 2 mg/ml in HM, freshly prepared.
Method An overnight culture of HDl cry B is prepared in 15 ml of SA Trp and grown with aeration at 20C. The following morning, the culture is diluted 50-100 x in prewarmed HM medium to a starting cell concen-tration of 7.5 x 105 / ml. Silicon (2 ~1) is added to prevent foaming.
The culture is grown at 37C with moderate aeration for 3h 30 min., i.e. to a cell concentration of 2.5 x 108 _ 3 x 108/ml. Lysozyme is added to a final concentration of 200 ug/ml and 1 ml of cell suspension is incubated for 30 min. at 37C in a shaking water bath (150 rpm). The cell suspension is then centrifuged 1 min. at 10'000 g and the pellet is resuspended in 1 ml fresh HM at room temperature.
0.5 ml cell suspension is added to 50 ~1 SMM to which 100 ng-10 ~g of plasmid DNA have been added. The cells are transformed by addition of 1.5 ml of PEG solution, gentle mixing and a 2 min.
incubation at room temperature. 5 ml of HM is added to the cell suspension, which is gently but thoroughly mixed snd centrifuged for 20 min. at 3'000 g. The pellet i9 re~uspensed in 0.6 ml of HM and incubated 3h. at 37C in a shaking water bath (150 rpm) to allow expression. Appropriate dilutions are plated on LA plates for CFU
determination and on Tetracycline-containing LA plates for transformant selection.
1-2 x 103 transformants per ~g of intact plasmid DNA, with a frequency of 5 x 10 5 - 10 4 are obtained.
Case 130-4004 I~PROVEHENTS IN OR RELATING TO ORGANIC SYST~S
The present invention relates to a method of transforming Bacillus thuringiensis cells.
The terms "transforming" and "transformation", as used herein are intended to relate to a mechanism of genetic transfer whereby exogenous DNA is introduced in a recipient bacterium, thereby inducing genetic changes in said recipient bacterium.
Bacillus thuringiensis (BT) are gram-positive bacteria containing a crystal protein, the delta-endotoxin (DET) which is toxic to the larvae of a number of insects. Depending on the sub-species, BT is used as a selective biological pesticide against different pests. The sub-species thuringiensis, alesti and dendrolimus are for example pathogenic against Lepidoptera: the sub-species israelensis, darmstadiensis 73-E-10-2, kyushuensis and morrisoni PG14 against Diptera; the sub-species tenebrionis against Coleoptera; the sub-species kurstaki HD-l, kenyae, aizawai and colmeri against Lepidoptera and Diptera, whereas the sub-species dakota, indiana, tokokuensis and kumamotoensis are not known to be toxic to any pests.
From the industrial and ecological point of vlew lt ls deslrable to have additlonal biological pesticides with different e.g. higher or broader spectrwn of activity.
This aim can, for example, be achieved by the development of new isolates from nature, by conjugatlon of bacteria or by transformation of bacteria.
Thus new BT strains with interestlng actlvity have been isolated recently (e.g. var. tenebrionis with activity against beetles) and recent successes with regard to the conjugation of BT strains have been reported as well.
Transformation of bacteria has the advantage that, if successful, it allows the introduction of specific genetic information into bacteria.
-` 13~7~. 5 Thus a gene coding for a DET has been cloned in various micro-organisms such as Escherichia coli, Bacillus subtilis and Pseudomonas fluorescens and even in higher plants (tobacco) by recombinant DNA
techniques, more specifically by transformation.
Such genetically manipulated organisms produce however low amounts of DET compared to the amounts produced by natural BT strains.
The commercial value of such organisms is accordingly questionable, at least as long as no way has been found to improve the expression of the exogenous DNA encoding for DET.
It would accordingly appear indicated to try and obtain a better expression of exogenous genes (DNA) by using a BT bacterium as recipient bacterium in transformation techniques.
Known transformation techniques are essentially effected employing either cells or protoplasts.
The transformation of cells implies the presence of competent cells, i.e. cells in a precise physiological stage allowing binding and uptake of exogenous DNA. There is however no evidence for the existence of competent BT cells.
The transformation of BT protoplasts by DNA has been reported to succeed only in very low yields, i.e. substantially lower than those obtained with the transformation of B. subtilis. The low yields may be partly due to the poor regeneration of the protoplasts, including the transformed protoplast. Although Shall et al. (Fundamental and applied aspects of invertebrate Pathology, edited by R.A. Samson, J.M. Vlak and D. Peters, 1986, page 402) report that they optimized the protoplasting procedure and developed improved regeneration media to transform BT or B. cereus with plasmid DNA, they do not specify the nature of the optimization or improvement.
The transformation frequencies indicated by Shall et al. are accordingly difficult to interprete.
The present invention now provides an improved method of transforming BT. It is based on the finding that BT microorganisms develop a so-called competence status when they are introduced in a hypertonic aqueous medium.
'' ~3~7nS
_ 3 - 130-4004 The term hypertonic as used herein refers to a medium which is hypertonic vis a vis the conventional BT (cell culture or growth) media.
The method of the invention involves the steps of a) growing BT cells in a hypertonic aqueous medium b) introducing in the cell culture obtained by step a) and in the presence of polyethylene glycol, exogenous DNA while maintaining the hypertonic status, and c) isolating and resuspending the thus treated BT cells in hypertonic aqueous medium to allow expression.
In principle any compound which does not pass the semi-permeable cell membrane and is not metabolized by or toxic to BT cell may be employed to obtain the desired hypertonic status. In general, the desired hypertonic status will conveniently be achieved with the aid of saccharides, particularly mono- or disaccharides, which are not metabolized by BT. Suitable examples of such saccharides are sucrose and lactose.
The concentration of saccharides to be employed to achieved the desired hypertonic status is conveniently of the order of 0.4 M
saccharide per litre of aqueous medium or higher. In general, good results will be obtained with concentrations which are essentially isotonic with respect to the BT cytoplasm. Such osmotic status is in general obtained with a concentration of from 0.4 M to 0.5 M of saccharides per litre of aqueous medium. Hlgher saccharides concentrations may however be employed, but offer in general no advantages.
The term "hypertonic" employed hereinafter refers to a status or medium as specifled hereinbefore.
It is important that the hypertoni~ conditions are essentially maintained throughout the various steps a) to c) of the process.
The hypertonic aqueous media should be essentially neutral, i.e.
they should conveniently have a pH of 7 + 2, more preferably of 7 + 1.
In addition to the saccharides (to maintain the hypertonic 13~9~7~S
status) and eventually buffers (to maintain an essentially neutral status of the medium) other ingredients may and will be added e.g. to allow growth and development of the BT culture when required, etc.
Such additional ingredients are conventional and known by those skilled in the art, they comprise e.g. nutrients and salts.
Examples of suitable nutrients are e.g. beef extract, yeast extract, peptones, tryptones, amino acids (e.g. tryptophan), nucleosides such as thymidine and the like.
Examples of suitable salts are NaCl and MgC12.6H20. A suitable hypertonic medium may contain from 0.05 to 0.1 M of salts per litre.
The salts wil comprise preferably magnesium salts, such as MgC12.6H20.
The BT cell culture (starting material) will conveniently be prepared and grown under conventional conditions, i.e. with aeration and at ambient temperature, in an appropriate nutrient medium, e.g. in the minimal medium disclosed by J. Spizizen in Proc. natl. Acad. Sci.
(Wash) 44, 171-175 (1958), eventually supplemented with amino acids, salts, e.g. catalytic amounts of a manganese salt such as MnS04, etc.
It is advantageous to employ in step a) a BT cell culture which is in the exponential growth phase.
The freshly prepared BT cell culture is then diluted in a hypertonic medium to a starting cell concentration of substantially less then 109 cells per ml, e.g. of 104 to 106 cells per ml and the cell culture is grown, in said hypertonic medium up until a cell concentration of slightly less than 109 cells per ml, e.g. 108 to 5.108 cells per ml medium i9 obtained-The hypertonic medium employed to dilute the freshly prepared BTcell culture is conveniently at 20 to 40C, e.g. at 37C. The culture is then allowed to grow at this temperature. Thorough aeration should of course be ascertained. A slight amount of silicon is conveniently added to the cell culture medium to prevent foaming.
When the desired final cell concentration (o slightly less than 109 cells per ml) is reached, the thus prepared competent BT cells may be treated with DNA in the presence of polyethylene glycol (PEG), according to step b) of the process of the invention.
~3~g7~S
It is however advantageous to treat the competent BT cells, obtained according to step a) of the invention, with moderate concentrations of lysozyme in hypertonic medium, and to isolate and resuspend the lysozyme treated BT cells in hypertonic medium, before subjecting them to process b). The amount of lysozyme to be employed should be less than that normally used for the preparation of protoplasts. Such amount (concentration) will of course depend on various factors such as the osmotic pressure of the medium, its temperature, the desired reaction time etc. In general a suitable lysozyme concentration is of 20 to 300 microgram, e.g. of 200 microgram per ml of hypertonic aqueous medium (which is substantially lower than the 2 to 15 mg per ml which would be normally required for protoplasting purposes). Adequate distribution of lysozyme in the cell culture medium should be ascertained. The reaction time will i.a.
depend on the concentration and the quality of the lysozyme solution employed. The optimum reaction time may be determined by standard assays.
The reaction temperature is conveniently between 20 to 40C, preferably above room temperature, e.g. at about 37~C.
During the lysozyme treatment the hypertonic status, as specified above, should be maintained.
The treatment with lysozyme is then terminated by centrifugation of the cell suspension and resuspension of the pellet in hypertonic medium, conveniently at room temperature.
The thus prepared 3T cell culture - obtalned according to step a), optionally followed by treatment with lysozyme - is then treated with DNA, e.g. plasmid DNA, in the presence of polyethylene glycol (PEG). For that purpose, the DNA as well as the PEG are employed as suspensions/solutions in a hypertonic solutions, such that the osmotic pressure of the cell suspension remains essentially unchanged after addition of DNA and PEG to said cell suspension.
The amount of PEG employed will be conveniently selected such that its concentration in the BT cell culture lies within the range of from lOOg to 400g per litre, e.g. at 300~ per litre cell culture medium.
13047~S
The transformation step b) can essentially be effected under the conditions known to be appropriate for conventional protoplast transformation processes.
Accordingly, the selection of the appropriate amount and type of PEG and of the appropriate amount of DNA to be employed can conveniently be made by those skilled in the art of protoplast transformation.
Thus, an example of PEG suitable for use in this process is PEG
6000.
DNA amounts of from lO0 nanogram to 20 microgram per 108 to 109 BT cells will in general allow good results.
The incubation is convenien~ly effected with gentle mixing at room temperature. Tlle required incubation time is short, in general of the order of a few minutes (see the example).
The suspension comprising the transformed cells is then worked up employing conventional methods but while securing the hypertonic status of the solvent of the cells (when in solution/suspension). Thus the suspension is for example diluted with hypertonic solution, the suspension mixed, centrifuged and the pellet resuspended in hypertonic medium.
The resulting suspension is then incubated at a temperature of 20 to 40C, e.g. at 37C, to allow expression. The suspension is conveniently aerated, employing e.g. a shakin~ water bath. An appropriate incubation time ls 30 nlit1utes to .~ hours, more preferably between 2 to 4 hours, e.g. 3 hours.
Appropriate dilutions of the thus obtained cèll cultures may then be placed on culture plates for determination of colony forming units (CFU). The transformation frequency may be determined by known methods employing standard techniques such as antibiotic containing culture plates, visual observation etc.
The method of the present invention allows the transformation of BT cells in high yields. Transformation allows gene cloning of genomic libraries in BT cells, cloning and expression of DET genes in BT, cloning and expression of in vitro and in vivo modified DET genes in 13C~4~S
BT, the synthesis of useful polypeptides, etc.
Where the transformed BT cells are intended for use as biological pesticides they are conveniently employed in insecticidal composition form, e.g. in suspension concentrate form or powder form. Such compositions may be obtained in conventional manner.
In the following non-limitative example the starting materials (BT cells and plasmid DNA) were selected such that the results are unambigous and cannot be due to plasmid interaction; the BT cells used as starting material did not contain plasmids, the plasmid DNA used as transforming agent encodes for resistance against tetra-cycline.
It will be appreciated that other BT cells and/or exogenous DNA, particularly plasmid DNA may be used in the method of the invention with similar results.
Temperatures are in centigrade and parts by weight unless specified otherwise.
- 13$~7(~5 EXAHPLE
Star_ing Materials Strain : Bacillus thuringiensis subsp. kurstaki HDl cry B, (obtained from M.-M. Lecadet, Institut Pasteur, Paris) having no plasmids.
DNA : pBC16.1 (Kraft. J. et al. (1978) Molec. gen. Genet. 162 :
59-67) extracted from HDl cry B (pBC16.1), in which it was introduced by conjugation via cell mating with B. subtilis BD224 (pBC16.1), coding for tetracycline resistance.
Media SA Trp : Spizizen minimal medium (Spizizen J. (1958) Proc. natl. Acad.
Scl (Wash.) 44 : 171-175) supplemented with 1% Casamino acids (Difco), 5xlO 6 M MnS04 and 20 ~g/ml Tryptophan.
Hypetonic medium (HM) :
Beef Extract1.50 g/l Peptone 5.00 g/l NaCl 3.50 g/l Sucrose171.15 g/l Maleic Acid2.32 g/l gC12 . 6H204.07 g/l pH 6.7 Luria Medium ~A? :
Tryptone 10 g/l Yeast Extract 5 g/l NaCl 10 g/l Agar (Difco Bacto) 15 g/l Thymidine20 mg/l Antibiotics : Tetracycline, 10-100 ~g/ml in LA plates 13~7(~5 Solutions SMM : Sucrose 171.15 g/l Maleic Acid 2.32 g/l gC12 . 6H204.07 g/l pH 6.5 PEG . PEG 6'000 40 g SMM ad 100 ml Lysozyme : 2 mg/ml in HM, freshly prepared.
Method An overnight culture of HDl cry B is prepared in 15 ml of SA Trp and grown with aeration at 20C. The following morning, the culture is diluted 50-100 x in prewarmed HM medium to a starting cell concen-tration of 7.5 x 105 / ml. Silicon (2 ~1) is added to prevent foaming.
The culture is grown at 37C with moderate aeration for 3h 30 min., i.e. to a cell concentration of 2.5 x 108 _ 3 x 108/ml. Lysozyme is added to a final concentration of 200 ug/ml and 1 ml of cell suspension is incubated for 30 min. at 37C in a shaking water bath (150 rpm). The cell suspension is then centrifuged 1 min. at 10'000 g and the pellet is resuspended in 1 ml fresh HM at room temperature.
0.5 ml cell suspension is added to 50 ~1 SMM to which 100 ng-10 ~g of plasmid DNA have been added. The cells are transformed by addition of 1.5 ml of PEG solution, gentle mixing and a 2 min.
incubation at room temperature. 5 ml of HM is added to the cell suspension, which is gently but thoroughly mixed snd centrifuged for 20 min. at 3'000 g. The pellet i9 re~uspensed in 0.6 ml of HM and incubated 3h. at 37C in a shaking water bath (150 rpm) to allow expression. Appropriate dilutions are plated on LA plates for CFU
determination and on Tetracycline-containing LA plates for transformant selection.
1-2 x 103 transformants per ~g of intact plasmid DNA, with a frequency of 5 x 10 5 - 10 4 are obtained.
Claims (12)
1. Process of transforming Bacillus thuringiensis cells comprising the steps a) growing Bacillus thuringiensis cells in a hypertonic aqueous medium b) introducing in the cell culture obtained by step a) and in the presence of polyethylene glycol, exogenous DNA while maintaining the hypertonic status and c) isolating and resuspending the thus treated Bacillus thuringiensis cell in hypertonic aqueous medium to allow expression.
2. The process of Claim 1, whereby the Bacillus thuringiensis cell culture of step a) is treated with moderate concentrations of lysozyme while maintaining the hypertonic conditions, and the thus treated Bacillus thuringiensis cells are then isolated and resuspended in hypertonic aqueous medium prior to the treatment according to steps b) and c).
3. The process of Claim 2, wherein the hypertonic status is obtained employing saccharides which are not metabolized by Bacillus thuringiensis.
4. The process of Claim 3, which comprises employing at least 0.4 M of saccharides per litre aqueous medium.
5. Process of Claim 1,2,3 or 4, wherein the initial Bacillus thuringiensis cell concentration introduced in step a) is of from 104 to 106 cells per ml medium and the cells are grown up to a concentration of from 108 to slightly less than 109 cells per ml medium.
6. The process of Claim 2,3 or 4 wherein the lysozyme concentration is of 20 to 300 microgram per millilitre aqueous medium.
7. The process of Claim 1,2,3 or 4, wherein the hypertonic medium has a pH in the range of 6 to 8.
8. The process of Claim 1,2,3 or 4, wherein the hypertonic medium comprises a magnesium salt
9. The process of Claim 1,2,3 or 4, effected at a temperature between 20 and 40°C.
10.The process of Claim 1,2,3 or 4, which comprises employing 100 nanogram to 20 microgram of DNA per 108 to 109 Bacillus thuringiensis cells.
11.The process of Claim 1,2,3 or 4, which comprises employing 100 to 400 g of polyethylene glycol per litre of cell culture.
12.The process of Claim 1,2,3 or 4, which comprises maintaining the hypertonic status of step c) for 30 minutes to 5 hours.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8630527 | 1986-12-22 | ||
GB868630527A GB8630527D0 (en) | 1986-12-22 | 1986-12-22 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1304705C true CA1304705C (en) | 1992-07-07 |
Family
ID=10609388
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000554916A Expired - Lifetime CA1304705C (en) | 1986-12-22 | 1987-12-21 | Organic systems |
Country Status (14)
Country | Link |
---|---|
JP (1) | JPS63181995A (en) |
AU (1) | AU611404B2 (en) |
BE (1) | BE1000309A4 (en) |
CA (1) | CA1304705C (en) |
CH (1) | CH674991A5 (en) |
DE (1) | DE3742429A1 (en) |
FR (1) | FR2608624B1 (en) |
GB (2) | GB8630527D0 (en) |
IE (1) | IE59334B1 (en) |
IL (1) | IL84890A (en) |
IT (1) | IT1230117B (en) |
NL (1) | NL8703070A (en) |
NZ (1) | NZ223013A (en) |
ZA (1) | ZA879616B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0342633B1 (en) * | 1988-05-20 | 1997-01-08 | Ciba-Geigy Ag | Transformation du Bacillus thuringiensis |
CN106544298B (en) * | 2016-10-27 | 2020-03-24 | 广东省微生物研究所 | Preparation method of bacillus subtilis competent cells |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57186492A (en) * | 1981-04-17 | 1982-11-16 | Kyowa Hakko Kogyo Co Ltd | Transformation of bacterium |
JPS60188069A (en) * | 1984-03-08 | 1985-09-25 | Nakano Vinegar Co Ltd | Transduction of cyclic dna into acetobacter |
GB8425487D0 (en) * | 1984-10-09 | 1984-11-14 | Agricultural Genetics Co | Strain of bacillus thuringiensis |
GB8523768D0 (en) * | 1985-09-26 | 1985-10-30 | Antibioticos Sa | Streptomyces wadayamensis |
-
1986
- 1986-12-22 GB GB868630527A patent/GB8630527D0/en active Pending
-
1987
- 1987-12-15 DE DE19873742429 patent/DE3742429A1/en not_active Withdrawn
- 1987-12-18 FR FR878717778A patent/FR2608624B1/en not_active Expired - Lifetime
- 1987-12-18 IT IT8748728A patent/IT1230117B/en active
- 1987-12-18 NL NL8703070A patent/NL8703070A/en not_active Application Discontinuation
- 1987-12-18 CH CH4951/87A patent/CH674991A5/de not_active IP Right Cessation
- 1987-12-21 NZ NZ223013A patent/NZ223013A/en unknown
- 1987-12-21 IL IL84890A patent/IL84890A/en not_active IP Right Cessation
- 1987-12-21 GB GB8729726A patent/GB2199044B/en not_active Expired - Lifetime
- 1987-12-21 CA CA000554916A patent/CA1304705C/en not_active Expired - Lifetime
- 1987-12-21 IE IE346887A patent/IE59334B1/en not_active IP Right Cessation
- 1987-12-21 BE BE8701466A patent/BE1000309A4/en not_active IP Right Cessation
- 1987-12-21 AU AU82866/87A patent/AU611404B2/en not_active Ceased
- 1987-12-21 JP JP62325160A patent/JPS63181995A/en active Pending
- 1987-12-22 ZA ZA879616A patent/ZA879616B/en unknown
Also Published As
Publication number | Publication date |
---|---|
IE873468L (en) | 1988-06-22 |
DE3742429A1 (en) | 1988-06-30 |
IT8748728A0 (en) | 1987-12-18 |
ZA879616B (en) | 1989-08-30 |
BE1000309A4 (en) | 1988-10-18 |
GB2199044B (en) | 1991-03-27 |
GB8630527D0 (en) | 1987-02-04 |
FR2608624A1 (en) | 1988-06-24 |
IL84890A0 (en) | 1988-06-30 |
AU611404B2 (en) | 1991-06-13 |
IT1230117B (en) | 1991-10-07 |
IL84890A (en) | 1992-12-01 |
CH674991A5 (en) | 1990-08-15 |
JPS63181995A (en) | 1988-07-27 |
GB8729726D0 (en) | 1988-02-03 |
GB2199044A (en) | 1988-06-29 |
AU8286687A (en) | 1988-06-23 |
NZ223013A (en) | 1991-01-29 |
IE59334B1 (en) | 1994-02-09 |
FR2608624B1 (en) | 1990-03-09 |
NL8703070A (en) | 1988-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1325393C (en) | Microorganisms | |
Tandeau de Marsac et al. | Expression of the larvicidal gene of Bacillus sphaericus 1593M in the cyanobacterium Anacystis nidulans R2 | |
Obukowicz et al. | Tn5-mediated integration of the delta-endotoxin gene from Bacillus thuringiensis into the chromosome of root-colonizing pseudomonads | |
US7670824B2 (en) | Multicopy-integration of heterologous genes and expression in Methylobacterium | |
WO1996029418A1 (en) | Introduction of dna into bacillus strains by conjugation | |
CA1339734C (en) | Bacillus thuringiensis transformation | |
Gaier et al. | Cloning and expression of the lysostaphin gene in Bacillus subtilis and Lactobadllus casei | |
JPH07501323A (en) | Novel coleopteran-active Bacillus thuringiensis isolates and genes encoding coleopteran-active toxins | |
CA1304705C (en) | Organic systems | |
US8097446B2 (en) | Staphylococus aureus strain CYL1892 | |
US5928897A (en) | Expression of a gram-positive bacteria replicon | |
EP0603416A1 (en) | METHOD OF INTEGRATING GENE INTO CHROMOSOME OF $i(LACTOBACILLUS DELBRUECKII) SPECIES AND PRODUCT OF GENE INTEGRATION | |
US5747310A (en) | Gene integration into chromosomes of lactobacillus delbrueckii species and integrants thereof | |
Workman et al. | Genetic engineering applications to biotechnology in the genus Bacillus | |
Prozorov | Conjugation in bacilli | |
JP2002508669A (en) | Protein producing cells containing multiple copies of the desired gene and a screenable marker rather than a selectable marker | |
WO2001066776A2 (en) | Novel l-form bacterial strains, method for producing same and the use thereof for producing gene products | |
CA1288710C (en) | Amylase-negative asporogenous mutant of bacillus subtilis useful as a host in a host-vector system | |
JPH02219567A (en) | Bacillus sphaericus producing larvacidal toxin obtained by means of gene engineering from bacillus turingiensis mutated israelensis | |
Clark et al. | The Bacillus thuringiensis genetic systems | |
Castet et al. | Improvement of plasmid stability of recombinant Bacillus-subtilis cells in continuous immobilized cultures | |
RU2103363C1 (en) | Recombinant plasmid dna pbtn 11 determining synthesis of crystalline insecticide delta-endotoxin cry iiia-type, method of its construction and strain of bacterium pseudomonas putida containing recombinant plasmid dna pbtn 11 - a producer of crystalline insecticide delta-endotoxin cry iiia-type showing activity against insects of coleoptera order | |
JPH02211862A (en) | Bacillus subtilis capable of producing anti-insect protein | |
Moosmayer et al. | Expression of scFv in L-Form Bacteria |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKLA | Lapsed |